DNA methylation in stress and depression: from bio... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

DNA methylation in stress and depression: from biomarker to therapeutics

Full text
Author(s):
Sales, Amanda J. [1] ; Guimaraes, Francisco S. [2, 1] ; Joca, Samia R. L. [2, 3]
Total Authors: 3
Affiliation:
[1] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Dept Pharmacol, Av Bandeirantes 3900, BR-14049900 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Ribeirao Preto, SP - Brazil
[3] Aarhus Univ, Dept Biomed, Ole Worms Alle 4, DK-8000 Aarhus C - Denmark
Total Affiliations: 3
Document type: Review article
Source: ACTA NEUROPSYCHIATRICA; v. 33, n. 5, p. 217-241, OCT 2021.
Web of Science Citations: 0
Abstract

Epigenetic mechanisms such as DNA methylation (DNAm) have been associated with stress responses and increased vulnerability to depression. Abnormal DNAm is observed in stressed animals and depressed individuals. Antidepressant treatment modulates DNAm levels and regulates gene expression in diverse tissues, including the brain and the blood. Therefore, DNAm could be a potential therapeutic target in depression. Here, we reviewed the current knowledge about the involvement of DNAm in the behavioural and molecular changes associated with stress exposure and depression. We also evaluated the possible use of DNAm changes as biomarkers of depression. Finally, we discussed current knowledge limitations and future perspectives. (AU)

FAPESP's process: 18/15896-3 - Participation of DNA methylation in rapid and sustained antidepressant-like effects induced by Cannabidiol and Ketamine
Grantee:Amanda Juliana Sales
Support Opportunities: Scholarships in Brazil - Post-Doctoral